Literature DB >> 16343368

Adjuvant chemotherapy for non-small cell lung cancer.

Edward J Crane1, George Simon.   

Abstract

Studies of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) did not provide a consistent disease-free survival or overall survival benefit in the 1980s and early 1990s. However, recently reported studies have changed the practice of NSCLC treatment, for which adjuvant chemotherapy is now considered the standard of care. This review outlines the issues that may have limited the detection of beneficial effects of adjuvant chemotherapy in early trials and provides detailed analysis of the results of recently published trials of adjuvant chemotherapy for NSCLC.

Entities:  

Mesh：

Year:  2006        PMID： 16343368     DOI： 10.1007/s11864-006-0031-8

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  14 in total

1.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

Authors:  Harubumi Kato; Yukito Ichinose; Morio Ohta; Enjo Hata; Noriaki Tsubota; Hirohito Tada; Yoh Watanabe; Hiromi Wada; Masahiro Tsuboi; Nobuyuki Hamajima; Mitsuo Ohta
Journal:  N Engl J Med       Date:  2004-04-22       Impact factor: 91.245

Review 2.  The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer.

Authors:  Giorgio V Scagliotti
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

3.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Authors:  Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

4.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

Authors:  Giorgio V Scagliotti; Roldano Fossati; Valter Torri; Lucio Crinò; Giuseppe Giaccone; Giovanni Silvano; Massimo Martelli; Maurizia Clerici; Francesco Cognetti; Maurizio Tonato
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

5.  A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304).

Authors:  Hirohito Tada; Ryosuke Tsuchiya; Yukito Ichinose; Teruaki Koike; Nobuhiro Nishizawa; Kanji Nagai; Harubumi Kato
Journal:  Lung Cancer       Date:  2004-02       Impact factor: 5.705

6.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

Authors:  D Waller; M D Peake; R J Stephens; N H Gower; R Milroy; M K B Parmar; R M Rudd; S G Spiro
Journal:  Eur J Cardiothorac Surg       Date:  2004-07       Impact factor: 4.191

7.  Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.

Authors: 
Journal:  Lancet       Date:  1998-07-25       Impact factor: 79.321

8.  Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.

Authors:  R Feld; L Rubinstein; P A Thomas
Journal:  J Natl Cancer Inst       Date:  1993-02-17       Impact factor: 13.506

9.  Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick; M H Veeder; J A Mailliard
Journal:  Ann Intern Med       Date:  1995-03-01       Impact factor: 25.391

10.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

Authors: 
Journal:  BMJ       Date:  1995-10-07
View more
  1 in total

1.  Effect of etoposide-induced alteration of the Mdm2-Rb signaling pathway on cellular senescence in A549 lung adenocarcinoma cells.

Authors:  Wenjing Dai; Yi Jiang; Kairong Chen; Jing Qiu; Jian Sun; Wei Zhang; Xiafei Zhou; Na Huang; Yunhui Li; Wancheng Li
Journal:  Oncol Lett       Date:  2017-07-27       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.